Leflunomide suppresses growth in human medullary thyroid cancer cells

• Published in: The Journal of surgical research Vol. 185; no. 1; pp. 212 - 216
• Main Authors: Alhefdhi, Amal, MD, Burke, Jocelyn F., MD, Redlich, Aaron, BS, Kunnimalaiyaan, Muthusamy, PhD, Chen, Herbert, MD, FACS
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2013
• Subjects: Antineoplastic Agents - pharmacology; Antirheumatic Agents - pharmacology; Basic Helix-Loop-Helix Transcription Factors - metabolism; Biomarkers - metabolism; Carcinoma, Medullary - drug therapy; Carcinoma, Medullary - metabolism; Carcinoma, Medullary - pathology; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation - drug effects; Chromogranin A - metabolism; Dose-Response Relationship, Drug; Down-Regulation - drug effects; Humans; Isoxazoles - pharmacology; Leflunomide (LFN); Medullary thyroid cancer (MTC); Neuroendocrine tumors; Surgery; Thyroid Neoplasms - drug therapy; Thyroid Neoplasms - metabolism; Thyroid Neoplasms - pathology; Medullary thyroid cancer (MTC); Leflunomide (LFN); Neuroendocrine tumors
• ISSN: 0022-4804; 1095-8673
• DOI: 10.1016/j.jss.2013.05.089

Abstract Background Medullary thyroid cancer (MTC) is a neuroendocrine tumor that arises from the calcitonin-secreting parafollicular cells of the thyroid gland. Leflunomide (LFN) is a disease-modifying antirheumatic drug approved for the treatment of rheumatoid arthritis, and its active metabolite teriflunomide has been identified as a potential anticancer drug. In this study we investigated the ability of LFN to similarly act as an anticancer drug by examining the effects of LFN treatment on MTC cells. Methods Human MTC-TT cells were treated with LFN (25–150 μmol/L) and Western blotting was performed to measure levels of neuroendocrine markers. MTT assays were used to assess the effect of LFN treatment on cellular proliferation. Results LFN treatment downregulated neuroendocrine markers ASCL1 and chromogranin A. Importantly, LFN significantly inhibited the growth of MTC cells in a dose-dependent manner. Conclusions Treatment with LFN decreased neuroendocrine tumor marker expression and reduced the cell proliferation in MTC cells. As the safety of LFN in human beings is well established, a clinical trial using this drug to treat patients with advanced MTC may be warranted.